Anzeige
Mehr »
Mittwoch, 02.07.2025 - Börsentäglich über 12.000 News
Nach dem Genius Act: Dieses börsennotierte XRP-Unternehmen greift im Token-Finanzmarkt an!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A404JF | ISIN: US8964385046 | Ticker-Symbol: TRB
NASDAQ
01.07.25 | 21:59
0,698 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TRINITY BIOTECH PLC ADR Chart 1 Jahr
5-Tage-Chart
TRINITY BIOTECH PLC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
0,5000,52025.06.

Aktuelle News zur TRINITY BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiTrinity Biotech plc: Trinity Biotech Reaches Profitability Inflection Point, Marking Major Milestone in Strategic Turnaround8
24.06.TRINITY BIOTECH PLC - 6-K, Report of foreign issuer3
24.06.Trinity Biotech plc: Trinity Biotech Secures Key Regulatory Approval for Offshored and Outsourced Manufacturing of Its Flagship Rapid HIV Test, Accelerating Strategic & Financial Performance Transformation10
15.05.Trinity Biotech plc: Trinity Biotech Publishes Fourth Quarter and Fiscal Year 2024 Financial Results & Provides a Business Update210DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable...
► Artikel lesen
04.04.TRINITY BIOTECH PLC - 6-K, Report of foreign issuer5
TRINITY BIOTECH Aktie jetzt für 0€ handeln
21.03.Trinity Biotech files to sell 4.29M American Depositary Shares for holders9
14.03.Trinity Biotech receives Nasdaq non-compliance notice25
14.03.Trinity Biotech plc: Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Price Requirement249DUBLIN, March 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable...
► Artikel lesen
13.03.Trinity Biotech plc: Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring - Appoints Barclays to Advise on Ongoing Strategic Realignment Process222DUBLIN and PORTLAND, Ore., March 13, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions...
► Artikel lesen
13.03.TRINITY BIOTECH PLC - 6-K, Report of foreign issuer5
28.02.Trinity Biotech sichert sich 4 Millionen US-Dollar für CGM-Technologie-Wachstum6
28.02.Trinity Biotech secures $4m for CGM technology growth3
28.02.Trinity Biotech plc: Trinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company's Continuous Glucose Monitoring Technology185DUBLIN, Ireland, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including...
► Artikel lesen
28.02.TRINITY BIOTECH PLC - 6-K, Report of foreign issuer-
06.02.TRINITY BIOTECH PLC - 6-K, Report of foreign issuer-
06.02.Trinity Biotech reports leap in CGM system accuracy2
06.02.Trinity Biotech vermeldet Durchbruch in der Genauigkeit des CGM-Systems5
06.02.Trinity Biotech plc: Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial233DUBLIN, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable...
► Artikel lesen
28.01.TRINITY BIOTECH PLC - 6-K, Report of foreign issuer1
28.01.Trinity Biotech verkündet Durchbruch in CGM-Technologie16
Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1